Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP)

Hughes, TP; Hochhaus, A; Branford, S; Muller, MC; Foroni, L; Druker, BJ; Guilhot, F; Larson, RA; O'Brien, SG; Waltzman, RJ; Mone, M; Wehrle, E; Radich, JP; Goldman, JM

Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP)

Lookup NU author(s): Dr Michelle Muller, Professor Stephen O'Brien

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Publication metadata

Author(s): Hughes TP, Hochhaus A, Branford S, Muller MC, Foroni L, Druker BJ, Guilhot F, Larson RA, O'Brien SG, Waltzman RJ, Mone M, Wehrle E, Radich JP, Goldman JM

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: Blood: 50th Annual Meeting of the American Society of Hematology

Year of Conference: 2008

Pages: 129-130 no. 334

ISSN: 0006-4971

Publisher: American Society of Hematology

URL: http://abstracts.hematologylibrary.org/cgi/content/abstract/112/11/334

Library holdings: Search Newcastle University Library for this item

ISBN: 15280020

ePrints

Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP)

Downloads

Publication metadata

Share